動脈瘤性くも膜下出血薬の世界市場2020-2026:オピオイド鎮痛薬、カルシウム拮抗薬、抗けいれん薬、便軟化剤、浸透圧剤、その他の薬剤

QYResearchが発行した調査報告書(QYR20AP00083)
◆英語タイトル:Global Aneurysmal Subarachnoid Hemorrhage Drugs Industry Research Report, Growth Trends and Competitive Analysis 2020-2026
◆商品コード:QYR20AP00083
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年3月(※2024年版があります。お問い合わせください。)
◆ページ数:115
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当リサーチレポートでは、動脈瘤性くも膜下出血薬の世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、動脈瘤性くも膜下出血薬のグローバル市場動向、メーカー別競争状況、種類別市場規模(オピオイド鎮痛薬、カルシウム拮抗薬、抗けいれん薬、便軟化剤、浸透圧剤、その他の薬剤)、用途別市場規模(病院、その他)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・動脈瘤性くも膜下出血薬の種類別市場2015-2026:オピオイド鎮痛薬、カルシウム拮抗薬、抗けいれん薬、便軟化剤、浸透圧剤、その他の薬剤
・動脈瘤性くも膜下出血薬の用途別市場2015-2026:病院、その他
・動脈瘤性くも膜下出血薬の北米市場分析
・動脈瘤性くも膜下出血薬のアジア市場分析
・動脈瘤性くも膜下出血薬の中南米市場分析
・動脈瘤性くも膜下出血薬の中東・アフリカ市場分析
・関連企業情報:Arbor Pharmaceuticals、Edge Therapeutics、Johnson & Johnson、Mylan N.V、Orexo AB、Pfizer、Purdue Pharma、Pharmaxis、Sun Pharmaceutical Industries、Teva Pharmaceutical
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke caused by bleeding in the space surrounding the brain.The global aneurysmal subarachnoid hemorrhage drugs market is segmented based on drug class and region. Based on drug class, the market is segmented into opioid analgesic, calcium channel blocker, anticonvulsant, stool softener, osmotic agent/diuretic, and other drugs.
In 2019, the global Aneurysmal Subarachnoid Hemorrhage Drugs market size was US$ 151.9 million and is forecast to US$ 175.3 million in 2026, growing at a CAGR of 2.0% from 2020. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Aneurysmal Subarachnoid Hemorrhage Drugs.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Aneurysmal Subarachnoid Hemorrhage Drugs market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Aneurysmal Subarachnoid Hemorrhage Drugs market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Aneurysmal Subarachnoid Hemorrhage Drugs market. Readers of the report can become informed about current and future trends of the global Aneurysmal Subarachnoid Hemorrhage Drugs market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Aneurysmal Subarachnoid Hemorrhage Drugs markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Aneurysmal Subarachnoid Hemorrhage Drugs market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global Aneurysmal Subarachnoid Hemorrhage Drugs market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global Aneurysmal Subarachnoid Hemorrhage Drugs market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the Aneurysmal Subarachnoid Hemorrhage Drugs market is segmented into
Opioid Analgesic
Calcium Channel Blocker
Anticonvulsant
Stool Softener
Osmotic Agent
Other Drugs

Market Segment by Application, the Aneurysmal Subarachnoid Hemorrhage Drugs market is segmented into
Hospital
Others

This report includes the following manufacturers; we can also add the other companies as you want.
Arbor Pharmaceuticals
Edge Therapeutics
Johnson & Johnson
Mylan N.V
Orexo AB
Pfizer
Purdue Pharma
Pharmaxis
Sun Pharmaceutical Industries
Teva Pharmaceutical

The study objectives are:
To analyze and research the global Aneurysmal Subarachnoid Hemorrhage Drugs status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key Aneurysmal Subarachnoid Hemorrhage Drugs manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Aneurysmal Subarachnoid Hemorrhage Drugs are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Opioid Analgesic
1.3.3 Calcium Channel Blocker
1.3.4 Anticonvulsant
1.3.5 Stool Softener
1.3.6 Osmotic Agent
1.3.7 Other Drugs
1.4 Market Segment by Application
1.4.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hospital
1.4.3 Others
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2015-2026)
2.1.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (2015-2026)
2.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (2015-2026)
2.2 Aneurysmal Subarachnoid Hemorrhage Drugs Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Regions (2015-2020)
2.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Regions (2015-2020)
2.3 Global Top Aneurysmal Subarachnoid Hemorrhage Drugs Regions (Countries) Ranking by Market Size
2.4 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Trends
2.4.1 Aneurysmal Subarachnoid Hemorrhage Drugs Market Top Trends
2.4.2 Market Drivers
2.4.3 Aneurysmal Subarachnoid Hemorrhage Drugs Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Aneurysmal Subarachnoid Hemorrhage Drugs Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturers by Sales (2015-2020)
3.1.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Aneurysmal Subarachnoid Hemorrhage Drugs Sales in 2019
3.2 Global Top Manufacturers Aneurysmal Subarachnoid Hemorrhage Drugs by Revenue
3.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Aneurysmal Subarachnoid Hemorrhage Drugs as of 2019)
3.4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Aneurysmal Subarachnoid Hemorrhage Drugs Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Aneurysmal Subarachnoid Hemorrhage Drugs Market
3.7 Key Manufacturers Aneurysmal Subarachnoid Hemorrhage Drugs Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Historic Market Review by Type (2015-2020)
4.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Type (2015-2020)
4.1.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Type (2015-2020)
4.1.4 Aneurysmal Subarachnoid Hemorrhage Drugs Price by Type (2015-2020)
4.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast by Type (2021-2026)
4.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast by Type (2021-2026)
4.2.4 Aneurysmal Subarachnoid Hemorrhage Drugs Price Forecast by Type (2021-2026)

5 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Size by Application
5.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Historic Market Review by Application (2015-2020)
5.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Application (2015-2020)
5.1.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Market Share by Application (2015-2020)
5.1.4 Aneurysmal Subarachnoid Hemorrhage Drugs Price by Application (2015-2020)
5.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast by Application (2021-2026)
5.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast by Application (2021-2026)
5.2.4 Aneurysmal Subarachnoid Hemorrhage Drugs Price Forecast by Application (2021-2026)

6 North America
6.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Company
6.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Type
6.3 North America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Application
6.4 North America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Countries
6.4.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Countries
6.4.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Company
7.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Type
7.3 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Application
7.4 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Countries
7.4.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Countries
7.4.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Company
8.2 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Type
8.3 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Application
8.4 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Regions
8.4.1 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Regions
8.4.2 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Company
9.2 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Type
9.3 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Application
9.4 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Countries
9.4.1 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Countries
9.4.2 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Type
10.2 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Application
10.3 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Breakdown Data by Countries
10.3.1 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Countries
10.3.2 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Arbor Pharmaceuticals
11.1.1 Arbor Pharmaceuticals Corporation Information
11.1.2 Arbor Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.1.5 Arbor Pharmaceuticals SWOT Analysis
11.1.6 Arbor Pharmaceuticals Recent Developments
11.2 Edge Therapeutics
11.2.1 Edge Therapeutics Corporation Information
11.2.2 Edge Therapeutics Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Edge Therapeutics Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Edge Therapeutics Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.2.5 Edge Therapeutics SWOT Analysis
11.2.6 Edge Therapeutics Recent Developments
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Corporation Information
11.3.2 Johnson & Johnson Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Johnson & Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Johnson & Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.3.5 Johnson & Johnson SWOT Analysis
11.3.6 Johnson & Johnson Recent Developments
11.4 Mylan N.V
11.4.1 Mylan N.V Corporation Information
11.4.2 Mylan N.V Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.4.5 Mylan N.V SWOT Analysis
11.4.6 Mylan N.V Recent Developments
11.5 Orexo AB
11.5.1 Orexo AB Corporation Information
11.5.2 Orexo AB Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.5.5 Orexo AB SWOT Analysis
11.5.6 Orexo AB Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.6.5 Pfizer SWOT Analysis
11.6.6 Pfizer Recent Developments
11.7 Purdue Pharma
11.7.1 Purdue Pharma Corporation Information
11.7.2 Purdue Pharma Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.7.5 Purdue Pharma SWOT Analysis
11.7.6 Purdue Pharma Recent Developments
11.8 Pharmaxis
11.8.1 Pharmaxis Corporation Information
11.8.2 Pharmaxis Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.8.5 Pharmaxis SWOT Analysis
11.8.6 Pharmaxis Recent Developments
11.9 Sun Pharmaceutical Industries
11.9.1 Sun Pharmaceutical Industries Corporation Information
11.9.2 Sun Pharmaceutical Industries Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.9.5 Sun Pharmaceutical Industries SWOT Analysis
11.9.6 Sun Pharmaceutical Industries Recent Developments
11.10 Teva Pharmaceutical
11.10.1 Teva Pharmaceutical Corporation Information
11.10.2 Teva Pharmaceutical Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Products and Services
11.10.5 Teva Pharmaceutical SWOT Analysis
11.10.6 Teva Pharmaceutical Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Aneurysmal Subarachnoid Hemorrhage Drugs Sales Channels
12.2.2 Aneurysmal Subarachnoid Hemorrhage Drugs Distributors
12.3 Aneurysmal Subarachnoid Hemorrhage Drugs Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.1.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast by Regions (2021-2026)
13.1.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.2.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast (2021-2026)
13.2.3 North America Aneurysmal Subarachnoid Hemorrhage Drugs Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.3.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast (2021-2026)
13.3.3 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.4.2 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.5.2 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast (2021-2026)
13.5.3 Latin America Aneurysmal Subarachnoid Hemorrhage Drugs Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

...

【掲載企業】

Arbor Pharmaceuticals、Edge Therapeutics、Johnson & Johnson、Mylan N.V、Orexo AB、Pfizer、Purdue Pharma、Pharmaxis、Sun Pharmaceutical Industries、Teva Pharmaceutical

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 動脈瘤性くも膜下出血薬の世界市場2020-2026:オピオイド鎮痛薬、カルシウム拮抗薬、抗けいれん薬、便軟化剤、浸透圧剤、その他の薬剤(Global Aneurysmal Subarachnoid Hemorrhage Drugs Industry Research Report, Growth Trends and Competitive Analysis 2020-2026)]についてメールでお問い合わせはこちらでお願いします。